Cadian Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Cadian Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,955,901	Closed	-$13.9M	–	31
2020 Q1	$13.9M	Sell	1,955,901 -177,442	-8%	-$2.21M	0.69%	22
2019 Q4	$50.9M	Sell	2,133,343 -1,533,694	-42%	-$42.3M	2.25%	17
2019 Q3	$98.3M	Sell	3,667,037 -424,650	-10%	-$11.9M	4.68%	10
2019 Q2	$111M	Buy	4,091,687 +116,789	+3%	+$3.66M	5.01%	7
2019 Q1	$138M	Sell	3,974,898 -2,487,707	-38%	-$71.8M	5.38%	6
2018 Q4	$126M	Buy	6,462,605 +2,309,210	+56%	+$47.5M	5.87%	5
2018 Q3	$111M	Buy	4,153,395 +1,873,194	+82%	+$61.2M	5.02%	8
2018 Q2	$86.1M	Buy	2,280,201 +1,039,257	+84%	+$39.8M	4.15%	12
2018 Q1	$40.5M	Sell	1,240,944 -283,499	-19%	-$12.4M	2.19%	15
2017 Q4	$74.2M	Buy	1,524,443 +357,700	+31%	+$18.1M	4.52%	9
2017 Q3	$63M	Buy	1,166,743 +840,700	+258%	+$49.4M	2.95%	12
2017 Q2	$18.3M	Sell	326,043 -542,357	-62%	-$21.7M	0.89%	32
2017 Q1	$34M	Buy	+868,400	New	+$27.7M	1.63%	22

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

Cadian Capital Management's PTLA Position: Q2 2020 in Review

Cadian Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 1,955,901 shares — an estimated $13.9M sold.

Cadian Capital Management first reported a position in PTLA in Q1 2017 and held it in 13 quarters. The position peaked at $138M in Q1 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Cadian Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Cadian Capital Management sold 1,955,901 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $13.9M.
Cadian Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2017 and held it in 13 quarters.
Cadian Capital Management's Portola Pharmaceuticals, Inc. position peaked at $138M in Q1 2019.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Cadian Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.